QIAGEN N.V. (NYSE:QGEN) agreed to acquire Digital PCR Program assets of Formulatrix, Inc. for $260 million on December 31, 2018. Consideration includes $125 million in cash and future milestone payments of up to approximately $135 million. The cash consideration is to be funded from existing cash reserves. Transaction is subject to customary closing conditions including regulatory approvals and U.S. clearance under the Hart-Scott-Rodino Act. Transaction is expected to close by mid-2019. Transaction is expected to be dilutive to full-year 2019, adjusted EPS by about $0.03 per share and neutral in 2020.